Reasons for the current stagnation of progress include failure of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) to show preventive activity of selenium and vitamin E; the failure of a high-risk phase III study to show preventive activity of selenized yeast; the refusal of the Food and Drug Administration to approve finasteride for prostate cancer prevention; and uncertainty regarding the long-term effects of treatment with 5-alpha reductase inhibitors
, according to Dr.
As we stated earlier, 5-alpha reductase inhibitor
drugs like finasteride (Proscar[R]) and dutasteride (Avodart[R]), markedly shrink prostate gland volume, thus making detection of tumors much more efficient.
In PCPT, the use of the 5-alpha reductase inhibitor
finasteride (Proscar) initially led to a 25% reduced risk of prostate cancer, but the medication also was associated with an increased risk of high-grade tumors.
Half of the respondents indicated they would try an alpha-blocker alone, one-third would initiate an alpha-blocker in combination with an anti-inflammatory, 11% would recommend triple therapy with an alpha-blocker, anti-inflammatory and 5-alpha reductase inhibitor
, and 6% would initiate neuromodulatory therapy (e.
0 or lower should consider taking a 5-alpha reductase inhibitor
to prevent prostate cancer, according to newly released clinical practice guidelines.
Avodart is the first and only 5-alpha reductase inhibitor
(5ARI) that inhibits both the type 1 and 2 isoenzymes of 5-alpha reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in the prostate and other tissues.
LIF is one of the four Ares-Serono projects to have advanced recently into pre-clinical development, the three others being: IFNAR 2, IL-18 binding protein, and a novel type I 5-alpha reductase inhibitor
Alpha blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha reductase inhibitor
8] Two studies have shown that 5-alpha reductase inhibitors
(5ARIs) reduce the risk of prostate cancer.
20) The current approach for medical management of LUTS associated with BPH depends on the usage of alpha-1 receptor blockers, such as alfuzosin, doxazosin, silodosin, tamsulosin and terazosin or suppression of the hormonal growth of the prostate by the 5-alpha reductase inhibitors
finasteride and dutasteride.